A previously published pan-cancer analysis of 30 solid tumor types showed that patients with MUC16 mutations showed higher tumor mutation burden and neoantigen burden, indicating increased tumor immunogenicity, which can predict immune checkpoint inhibitor treatment response. Here, MUC16 is linked to cancer.